阿司咪唑(astemizole,AST)为选择性H_1受体拮抗剂,由于具有长效且无中枢镇静作用的特点,在临床广为应用,不良反应也时有报道。现对国内文献报道的AST不良反应52例进行综合分析,报告如下: 52例中,男21例,女31例,年龄45～56岁,其中心血管系统13例,占25％;神经系统3例,占5.77％;过敏反应25例,占48.08％;其不良反应11例,占21.15 Astemizole (AST) is a selective H_ (1) receptor antagonist. Due to its long-lasting and non-central sedative effect, astemizole (AST) has been widely used clinically and adverse reactions have been reported from time to time. Now reported in the literature of AST adverse reactions in 52 cases were analyzed as follows: 52 cases, 21 males and 31 females, aged 45 to 56 years old, of which 13 cases of cardiovascular system, accounting for 25%; nervous system 3 Cases, accounting for 5.77%; 25 cases of allergic reactions, accounting for 48.08%; 11 cases of adverse reactions, accounting for 21.15